Expression of osteoprotegerin in human fat tissue; implications for chronic kidney disease

European Journal of Clinical Investigation

Volumn 41, Issue 5, 2011, Pages 498-506

  Witasp, Anna ^a   Carrero, Juan J ^a,b   Hammarqvist, Folke ^c   Qureshi, Abdul R ^c   Heimbürger, Olof ^c   Schalling, Martin ^a   Lindholm, Bengt ^c   Nordfors, Louise ^a   Stenvinkel, Peter ^c  

^a Department of Molecular Medicine and Surgery ^*  (Sweden)

^b Centre for Gender Medicine   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

End stage renal disease; Osteoprotegerin; Uremic fat

Indexed keywords

MESSENGER RNA; OSTEOPROTEGERIN;

ADIPOSE TISSUE; ADULT; AGED; ARTICLE; CHOLECYSTECTOMY; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; HERNIOPLASTY; HUMAN; LAPAROSCOPIC SURGERY; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADIPOSE TISSUE; ADULT; AGED; BLOOD PROTEINS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OSTEOPROTEGERIN; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79953749696     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02432.x     Document Type: Article

References (45)

1. Cannata-Andia JB, Rodriguez-Garcia M, Carrillo-Lopez N, Naves-Diaz M, Diaz-Lopez B. Vascular calcifications: pathogenesis, management, and impact on clinical outcomes. J Am Soc Nephrol 2006;17:S267-73.
2. Suliman ME, Garcia-Lopez E, Anderstam B, Lindholm B, Stenvinkel P. Vascular calcification inhibitors in relation to cardiovascular disease with special emphasis on fetuin-A in chronic kidney disease. Adv Clin Chem 2008;46:217-62.
3. Kalantar-Zadeh K, Kopple JD. Obesity paradox in patients on maintenance dialysis. Contrib Nephrol 2006;151:57-69.
4. Cordeiro AC, Qureshi AR, Stenvinkel P, Heimburger O, Axelsson J, Barany P et al. Abdominal fat deposition is associated with increased inflammation, protein-energy wasting and worse outcome in patients undergoing haemodialysis. Nephrol Dial Transplant 2010;25:562-8.
5. Postorino M, Marino C, Tripepi G, Zoccali C. Abdominal obesity and all-cause and cardiovascular mortality in end-stage renal disease. J Am Coll Cardiol 2009;53:1265-72.
6. Carrero JJ, Cordeiro AC, Lindholm B, Stenvinkel P. The emerging pleiotrophic role of adipokines in the uremic phenotype. Curr Opin Nephrol Hypertens 2010;19:37-42.
7. Shinoda Y, Yamaguchi M, Ogata N, Akune T, Kubota N, Yamauchi T et al. Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem 2006;99:196-208.
8. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000;100:197-207.
9. Gordeladze JO, Drevon CA, Syversen U, Reseland JE. Leptin stimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization: impact on differentiation markers, apoptosis, and osteoclastic signaling. J Cell Biochem 2002;85:825-36.
10. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007;130:456-69.
11. Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci U S A 2008;105:5266-70.
12. Gomez-Ambrosi J, Catalan V, Ramirez B, Rodriguez A, Colina I, Silva C et al. Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab 2007;92:3719-27.
13. Di Iorgi N, Rosol M, Mittelman SD, Gilsanz V. Reciprocal relation between marrow adiposity and the amount of bone in the axial and appendicular skeleton of young adults. J Clin Endocrinol Metab 2008;93:2281-6.
14. Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003;112:357-66.
15. Schinke T, Amendt C, Trindl A, Poschke O, Muller-Esterl W, Jahnen-Dechent W. The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem 1996;271:20789-96.
16. Szweras M, Liu D, Partridge EA, Pawling J, Sukhu B, Clokie C et al. alpha 2-HS glycoprotein/fetuin, a transforming growth factor-beta/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. J Biol Chem 2002;277:19991-7.
17. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003;361:827-33.
18. Lavebratt C, Dungner E, Hoffstedt J. Polymorphism of the AHSG gene is associated with increased adipocyte beta2-adrenoceptor function. J Lipid Res 2005;46:2278-81.
19. Lavebratt C, Wahlqvist S, Nordfors L, Hoffstedt J, Arner P. AHSG gene variant is associated with leanness among Swedish men. Hum Genet 2005;117:54-60.
20. Ix JH, Wassel CL, Chertow GM, Koster A, Johnson KC, Tylavsky FA et al. Fetuin-A and change in body composition in older persons. J Clin Endocrinol Metab 2009;94:4492-8.
21. Axelsson J, Wang X, Ketteler M, Qureshi AR, Heimburger O, Barany P et al. Is fetuin-A/alpha2-Heremans-Schmid glycoprotein associated with the metabolic syndrome in patients with chronic kidney disease? Am J Nephrol 2008;28:669-76.
22. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998;95:3597-602.
23. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-8.
24. Kazama JJ, Shigematsu T, Yano K, Tsuda E, Miura M, Iwasaki Y et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 2002;39:525-32.
25. Barreto DV, Barreto FC, Carvalho AB, Cuppari L, Cendoroglo M, Draibe SA et al. Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors. Kidney Int 2005;67:1576-82.
26. Morena M, Terrier N, Jaussent I, Leray-Moragues H, Chalabi L, Rivory JP et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 2006;17:262-70.
27. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
28. An JJ, Han DH, Kim DM, Kim SH, Rhee Y, Lee EJ et al. Expression and regulation of osteoprotegerin in adipose tissue. Yonsei Med J 2007;48:765-72.
29. Fain JN, Buehrer B, Bahouth SW, Tichansky DS, Madan AK. Comparison of messenger RNA distribution for 60 proteins in fat cells vs the nonfat cells of human omental adipose tissue. Metabolism 2008;57:1005-15.
30. Skopkova M, Penesova A, Sell H, Radikova Z, Vlcek M, Imrich R et al. Protein array reveals differentially expressed proteins in subcutaneous adipose tissue in obesity. Obesity (Silver Spring) 2007;15:2396-406.
31. Oh ES, Rhee EJ, Oh KW, Lee WY, Baek KH, Yoon KH et al. Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women. Metabolism 2005;54:49-54.
32. Holecki M, Zahorska-Markiewicz B, Janowska J, Nieszporek T, Wojaczynska-Stanek K, Zak-Golab A et al. The influence of weight loss on serum osteoprotegerin concentration in obese perimenopausal women. Obesity (Silver Spring) 2007;15:1925-9.
33. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999;55:1899-911.
34. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:RESEARCH0034.
35. Gomez-Ambrosi J, Rodriguez A, Catalan V, Fruhbeck G. The bone-adipose axis in obesity and weight loss. Obes Surg 2008;18:1134-43.
36. Nitta K, Akiba T, Uchida K, Otsubo S, Takei T, Yumura W et al. Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004;19:1886-9.
37. Stenvinkel P, Wang K, Qureshi AR, Axelsson J, Pecoits-Filho R, Gao P et al. Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney Int 2005;67:2383-92.
38. Nordfors L, Lonnqvist F, Heimburger O, Danielsson A, Schalling M, Stenvinkel P. Low leptin gene expression and hyperleptinemia in chronic renal failure. Kidney Int 1998;54:1267-75.
39. Marchlewska A, Stenvinkel P, Lindholm B, Danielsson A, Pecoits-Filho R, Lonnqvist F et al. Reduced gene expression of adiponectin in fat tissue from patients with end-stage renal disease. Kidney Int 2004;66:46-50.
40. Cianciolo G, La Manna G, Donati G, Persici E, Dormi A, Cappuccilli ML et al. Coronary calcifications in end-stage renal disease patients: a new link between osteoprotegerin, diabetes and body mass index? Blood Purif 2009;29:13-22.
41. Sigrist MK, Levin A, Er L, McIntyre CW. Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. Nephrol Dial Transplant 2009;24:3157-62.
42. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006;47:1850-7.
43. Carrero JJ, Stenvinkel P. Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal. Clin J Am Soc Nephrol 2009;4(Suppl 1):S49-55.
44. Matsubara K, Stenvinkel P, Qureshi AR, Carrero JJ, Axelsson J, Heimburger O et al. Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease. J Nephrol 2009;22:774-82.
45. Axelsson J, Rashid Qureshi A, Suliman ME, Honda H, Pecoits-Filho R, Heimburger O et al. Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr 2004;80:1222-9.